Difference between revisions of "Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5 (Q9904)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Volume (P103): 25, #quickstatements; #temporary_batch_1590009084631)
(‎Created claim: Page(s) (P105): 929-935, #quickstatements; #temporary_batch_1590074839150)
 
(One intermediate revision by the same user not shown)
Property / title
 +
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English)
Property / title: Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English) / rank
 +
Normal rank
Property / Page(s)
 +
929-935
Property / Page(s): 929-935 / rank
 +
Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Sullivan RJ
    0 references
    0 references
    2019
    0 references
    Nat. Med.
    0 references
    25
    0 references
    Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English)
    0 references
    929-935
    0 references